20.14
+7.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cue Biopharma
From its filings with the US Securities and Exchange Commission
Cue Biopharma is based in Somerville, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CUE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $27.5m and a net loss of $26.6m. At that date it held total assets of $42.2m and shareholders' equity of $26.4m.
We aim to leverage our differentiated platform to establish new standards of care, forge strategic partnerships, and accelerate clinical development.
As represented in the following image, the Immuno-STAT framework is engineered to be highly flexible and modular, potentially enabling us to deploy the same or similar core functional elements to restore immune balance across diverse therapeutic approaches.
In autoimmune disease, Tregs are the master regulators of maintaining immune homeostasis, or balance, and health. Autoreactive T cells, referred to as T effector cells (Teff cells), are reactive against “self” proteins and foster inflammation and induce chronic tissue damage. Tregs are important to maintaining immune balance in that they possess the ability to dampen and control the Teff cells.
Our lead candidate, CUE-401, is a preclinical, bifunctional fusion protein designed to promote immune tolerance by modulating key components of the immune system, including the induction of newly formed Tregs (iTregs) from Teff cells, the expansion of existing or natural regulatory T cells (nTregs), and the reduction of pro-inflammatory autoreactive cells. Through the co-activity of engineered variants of TGF-β and IL-2, CUE-401 has the therapeutic potential to re-establish immune balance and induce tolerance across a range of T cell mediated autoimmune and inflammatory diseases.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Jan 2018
- Employees
- 29
- Website
- cuebiopharma.com ↗
- Head office
- 100 CHESTNUT STREET, SOMERVILLE, MA, 02143
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Frank MorichIndependent Chairman of the Board$115,887
- Dr. Usman AzamPresident, Chief Executive Officer, Director, since 2025
- Mr. Colin SandercockSenior Vice President, General Counsel, Secretary$625,514
- Dr. Daniel BakerInterim Chief Development Officer
- Mr. Matteo LevisettiChief Medical Officer$1.2m
- Ms. Lucinda WarrenChief Business officer
- Mr. Jill BroadfootDirector
- Dr. Pamela GarzoneIndependent Director$95,750
- Dr. Peter KienerIndependent Director$219,750
- Mr. Pasha SarrafIndependent Director
- Mr. Patrick VerheyenIndependent Director$103,250
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 52
- Social
- 54
- Governance
- 40
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cue Biopharma Inc possesses several strengths that contribute to its success in the biopharmaceutical industry. These strengths include:
Weaknesses
- Despite its strengths, Cue Biopharma Inc also faces certain weaknesses that may hinder its growth prospects. These weaknesses include:
Opportunities
- Cue Biopharma Inc can take advantage of several opportunities to further enhance its position in the industry. These opportunities include:
Threats
- Cue Biopharma Inc should be aware of potential threats that could impede its progress and success. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.